PET LACE
The Impact of Positron Emission Tomography (PET) Imaging in Women With Locally Advanced Cervical Cancer
Sponsor study identifier
interventional
171
1 country
6
Study Start
April 2010
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
June 2014
Actual (reported)Study Completion
August 2019
Actual (reported)The purpose of this trial is to improve the clinical management and outcome of patients with locally advanced cervical cancer by using positron emission tomography-computed tomography (PET-CT) imaging. There is considerable debate worldwide regarding the utility of PET for staging cervical cancer. Although there are studies on the accuracy (sensitivity and specificity) of PET in cervical cancer, there are currently no prospective randomized studies on how PET information affects treatment decisions and outcomes.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
August 2019
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 6, 2009
Actual (reported)May 8, 2009
Actual (reported)April 2010
Date type not reportedThis date has not been verified as actual or estimated.
June 2014
Actual (reported)August 2019
Actual (reported)Treatment delivered between patients having whole body 18FDG PET-CT in addition to CT of the abdomen and pelvis versus patients having a CT of the abdomen and pelvis alone.
2 years
Event free survival (EFS) of all patients.
5 years
Overall Survival (OS) of all patients.
5 years
Economic and Quality of Life analyses of all patients.
CT Abdomen and Pelvis + whole body PET-CT
CT Abdomen and Pelvis
Pre-treatment scan
Pre-treatment scan
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Juravinski Cancer Centre
Hamilton, Ontario, L8V 5C2, Canada
London Health Sciences Centre - London Regional Cancer Program
London, Ontario, N6A 4L6, Canada
Ottawa Hospital Regional Cancer Centre
Ottawa, Ontario, K1H 8L6, Canada
Thunder Bay Regional Health Sciences Centre
Thunder Bay, Ontario, P7B 6V4, Canada
Odette Cancer Centre (Toronto-Sunnybrook)
Toronto, Ontario, M4N 3M5, Canada
Princess Margaret Hospital
Toronto, Ontario, M5G 2M9, Canada
Elit LM, Fyles AW, Gu CS, Pond GR, D'Souza D, Samant R, Anthes M, Thomas G, Filion M, Arsenault J, Dayes I, Whelan TJ, Gulenchyn KY, Metser U, Dhamanaskar K, Levine MN. Effect of Positron Emission Tomography Imaging in Women With Locally Advanced Cervical Cancer: A Randomized Clinical Trial. JAMA Netw Open. 2018 Sep 7;1(5):e182081. doi: 10.1001/jamanetworkopen.2018.2081.
Laurie Elit, MD
Juravinski Cancer Centre, Canada
Anthony Fyles, MD
Princess Margaret Hospital, Canada
Greg Pond, PhD
Ontario Clinical Oncology Group/McMaster University, Department of Oncology
Mark Levine, MD
Ontario Clinical Oncology Group/McMaster University, Department of Oncology
171 participants (actual enrollment reported by the registry).
First Submitted
May 6, 2009
First Posted
May 8, 2009
Study Start
April 2010
Date type not reportedThis date has not been verified as actual or estimated.
FDG-PET and Circulating HPV in Patients With Cervical Cancer
2 years
Standardized Uptake Value (SUV) in predicting the EFS and OS of all patients.
5 years
Contact the study team to confirm eligibility.
Karen Gulenchyn, MD
Hamilton Health Sciences Centre
Mostafa Atri, MD
University Health Network, Toronto
Douglas Coyle, PhD
University of Ottawa Epidemiology & Community Medicine
Primary Completion
June 2014
Actual (reported)Study Completion
August 2019
Actual (reported)Last Updated
January 29, 2020
Record last verified: 2020-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: